Branding & Marketing

MMIT Reality Check on Chronic Idiopathic Constipation (May 2019)

May 17, 2019

According to our recent payer coverage analysis for chronic idiopathic constipation treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for chronic idiopathic constipation treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for chronic idiopathic constipation treatments shows that under the pharmacy benefit, around 41% of the covered lives in commercial formularies are covered without utilization management restrictions.

Trends: This class is heavily contracted, with some PBMs excluding Trulance in favor of the older therapies Linzess and Amitiza. Via AIS Health.

MMIT Reality Check on Narcolepsy (May 2019)

May 10, 2019

According to our recent payer coverage analysis for narcolepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for narcolepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for narcolepsy treatments shows that under the pharmacy benefit, more than 66% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In March 2019, the FDA approved Jazz Pharmaceuticals plc’s Sunosi (solriamfetol) to improve wakefulness in adults with excessive daytime sleepiness from narcolepsy or obstructive sleep apnea. Via AIS Health.

MMIT Reality Check on Low Testosterone (May 2019)

May 3, 2019

According to our recent payer coverage analysis for low testosterone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for low testosterone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for low testosterone treatments due to chronic kidney disease shows that under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In March 2019, the FDA approved Jatenzo (testosterone undecanoate) for the treatment of males with low testosterone levels because of specific genetic disorders or pituitary gland-damaging tumors. Via AIS Health.

MMIT Reality Check on Anemia — Chronic Kidney Disease (Apr 2019)

April 26, 2019

According to our recent payer coverage analysis for anemia treatments due to chronic kidney disease, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for anemia treatments due to chronic kidney disease, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for anemia treatments due to chronic kidney disease shows that under the pharmacy benefit, more than 56% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In October 2018, UnitedHealthcare said that starting Jan. 1, 2019, it would require step therapy prior authorization for Part B covered items that are not preferred for new starts. The plan will prefer biosimilar Retacrit (epoetin alfaepbx) over Procrit (epoetin alfa) and Aranesp (darbepoetin alfa). Via AIS Health.

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2019)

April 19, 2019

According to our recent payer coverage analysis for ophthalmic anti-Inflammatory treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

19

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ophthalmic anti-Inflammatory treatments shows that under the pharmacy benefit, almost 64% and 42% of the lives under commercial formularies and Medicare formularies are covered without utilization management restrictions, respectively.

Trends: There are numerous products in the ophthalmic anti-inflammatory pipeline; many are new formulations or strengths of the same chemical entity, while only one is a new molecule. Via AIS Health.

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2019)

April 12, 2019

According to our recent payer coverage analysis for juvenile idiopathic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for juvenile idiopathic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for juvenile idiopathic arthritis treatments shows that under the pharmacy benefit, almost 70% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: There are multiple biosimilars in this class that have been approved by the FDA but will not launch until sometime between 2021 and 2023. Via AIS Health.